Skip to search formSkip to main contentSkip to account menu

24 HR rivastigmine 0.192 MG/HR Transdermal System

Known as: RIVASTIGMINE 4.6 mg in 24 h TRANSDERMAL PATCH, EXTENDED RELEASE [Rivastigmine], rivastigmine 4.6 MG/Day 24 HR Transdermal Patch, rivastigmine 0.192 MG/HR 24 HR Transdermal Patch 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (1)

24 HR rivastigmine 0.192 MG/HR Transdermal System [Exelon]
Alzheimer's DiseaseCarbamatesHypersensitivityMineral Oil, Light

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Stability-indicating high performance liquid chromatographic determination of rivastigmine with kinetic study of rivastigmine alkalinedegradation
Stability-indicating high performance liquid chromatographic determination of rivastigmine in its binary mixture with kinetic… 
2014
2014
Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease.
The present study discusses possibility of targeting an anti-Alzheimer's drug rivastigmine tartarate (RT) to the brain using… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)